Table 1.
Baseline characteristics and the clinical correlates of PR interval in the Health, Aging and Body Composition cohort (N=2722)
| Clinical Characteristics | Distribution | Age, sex, site, race adjusted | Multivariable adjusted | ||||||
|---|---|---|---|---|---|---|---|---|---|
| PR (continuous) | PR > 200 | PR (continuous) | PR > 200 | ||||||
| Change in PR ±SD | P | OR (95% CI) | P | Change in PR ±SD | P | OR (95% CI) | P | ||
| Age | 74 ± 3 | 1.7 ± 0.6 | 0.003 | 1.19 (1.06, 1.33) | 0.003 | 1.7 ± 0.5 | 0.002 | 1.19 (1.06, 1.34) | 0.004 |
| Female sex | 1427 (52.4) | −12.5 ± 1.1 | <.0001 | 0.36 (0.28, 0.46) | <.0001 | −12.4 ± 1.2 | <.0001 | 0.35 (0.26, 0.46) | <.0001 |
| Memphis site | 1372 (50.4) | −1.8 ± 1.1 | 0.010 | 0.92 (0.73, 1.15) | 0.48 | −0.4 ± 1.1 | 0.75 | 1.03 (0.80, 1.32) | 0.82 |
| Black race | 1115 (41.0%) | 1.4 ± 1.1 | 0.22 | 1.14 (0.90, 1.44) | 0.28 | −0.2 ± 1.2 | 0.84 | 1.03 (0.80, 1.34) | 0.82 |
| Smoking (current and former) | 1515 (55.7) | −3.1 ± 1.2 | 0.007 | 0.88 (0.69, 1.13) | 0.33 | −2.7 ± 1.1 | 0.016 | 0.91 (0.71, 1.16) | 0.44 |
| Body mass index | 27.4 ± 4.8 | 3.6 ± 0.6 | <.0001 | 1.26 (1.12, 1.42) | 0.0002 | 3.1 ± 0.6 | <.0001 | 1.22 (1.07, 1.39) | 0.003 |
| Systolic BP, mm Hg | 136 ± 21 | 0.9 ± 0.6 | 0.11 | 1.13 (1.01, 1.27) | 0.031 | −0.2 ± 0.7 | 0.82 | 1.05 (0.91, 1.21) | 0.52 |
| Diastolic BP, mm Hg | 71 ± 12 | −0.3 ± 0.6 | 0.61 | 1.02 (0.91, 1.16) | 0.71 | 0.2 ± 0.7 | 0.78 | 1.02 (0.88, 1.18) | 0.82 |
| Heart failure | 64 (2.4) | 6.8 ± 3.6 | 0.06 | 1.57 (0.83, 2.96) | 0.16 | 3.6 ± 3.6 | 0.32 | 1.31 (0.67, 2.55) | 0.43 |
| Coronary heart disease | 565 (20.8) | 5.2 ± 1.4 | 0.0002 | 1.28 (0.98, 1.66) | 0.07 | 1.7 ± 1.5 | 0.24 | 0.96 (0.71, 1.29) | 0.77 |
| Stroke | 214 (7.9) | 0.8 ± 2.1 | 0.70 | 1.09 (0.72, 1.66) | 0.68 | −0.9 ± 2.0 | 0.67 | 0.97 (0.63, 1.50) | 0.90 |
| Diabetes | 400 (14.7) | 2.4 ± 1.6 | 0.13 | 1.22 (0.90, 1.67) | 0.20 | 1.7 ± 1.6 | 0.27 | 1.17 (0.85, 1.63) | 0.34 |
| Total/HDL Cholesterol ratio | 4.1 ± 1.3 | 1.7 ± 0. 6 | 0.003 | 1.15 (1.03, 1.28) | 0.016 | 0.7 ± 0.6 | 0.19 | 1.09 (0.97, 1.22) | 0.17 |
| Hypertension treatment | 1459 (53.6) | 7. 3 ± 1.1 | <.0001 | 1.70 (1.34, 2.16) | <.0001 | 2.1 ± 1.4 | 0.14 | 1.12 (0.80, 1.56) | 0.52 |
| Selected medications | 1126 (41.3%) | 8.6 ± 1.1 | <.0001 | 1.91 (1.51, 2.42) | <.0001 | 4.8 ± 1.5 | 0.001 | 1.56 (1.12, 2.18) | 0.009 |
| Heart rate, beats per minute | 65 ± 11 | −4.9 ± 0.6 | <.0001 | 0.73 (0.64, 0.83) | <.0001 | −4.9 ± 0.6 | <.0001 | 0.73 (0.64, 0.83) | <.0001 |
| ECG left ventricular hypertrophy | 237 (8.7) | 5.2 ± 2.0 | 0.009 | 1.58 (1.09, 2.28) | 0.015 | 4.6 ± 1.9 | 0.016 | 1.47 (1.01, 2.16) | 0.047 |
| PR interval, ms | 168 (152, 188) | ||||||||
Distributions are means (SD) or n (%) for anthropometric, clinical, and laboratory variables. Age, sex, site and race adjusted models: each of age, sex, site and race was adjusted for the other three variables. Comprehensive multivariable adjustment included adjustment for age, sex, site and race and the remainder of the variables listed here. Selected medications are amiodarone, cardiac glycosides, calcium channel blockers, beta blockers. Continuous variables expressed per standard deviation and categorical for the presence of variable. Estimates show the change in PR interval per standard deviation change for continuous variables or for the presence of that variable for categorical variables. PR expressed as median and interquartile range. BP, blood pressure.